Article
Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.
The Lancet. Infectious diseases - 1 Mar 2016
Amaratunga Chanaki, Lim Pharath, Suon Seila, Sreng Sokunthea, Mao Sivanna, Sopha Chantha, Sam Baramey, Dek Dalin, Try Vorleak, Amato Roberto, Blessborn Daniel, Song Lijiang, Tullo Gregory S, Fay Michael P, Anderson Jennifer M, Tarning Joel, Fairhurst Rick M
Abstract excerpt
BACKGROUND: Artemisinin resistance in Plasmodium falciparum threatens to reduce the efficacy of artemisinin combination therapies (ACTs), thus compromising global efforts to eliminate malaria. Recent treatment failures with dihydroartemisinin-piperaquine, the current first-line ACT in Cambodia, suggest that piperaquine resistance may be emerging in this country. We explored the relation between artemisinin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.